Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Zacutex lexipafant platelet activating factor (PAF) antagonist: Phase III Update

Based on work done in the U.K., the U.S. trial was begun in 1996 and designed to enroll 450 patients. Patients receive either

Read the full 235 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE